

1                   **Ventral Tegmental Area GABA, glutamate, and glutamate-GABA neurons are heterogenous in their**  
2                   **electrophysiological and pharmacological properties**

3  
4  
5 Miranda-Barrientos Jorge<sup>1</sup>, Chambers Ian<sup>1</sup>, Mongia Smriti<sup>1</sup>, Liu Bing<sup>1</sup>, Wang Hui-Ling<sup>1</sup>, Mateo-Semidey Gabriel E<sup>1</sup>,  
6 Margolis Elyssa B<sup>2</sup>, Zhang Shiliang<sup>3</sup>, Morales Marisela<sup>1\*</sup>

7  
8  
9  
10 <sup>1</sup>Integrative Neuroscience Research Branch, National Institute on Drug Abuse, Baltimore, Maryland 21224. <sup>2</sup> UCSF Weill  
11 Institute of Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA 94158,  
12 USA. <sup>3</sup>Confocal and Electron Microscopy Core, National Institute on Drug Abuse, Baltimore, Maryland 21224

13  
14  
15  
16  
17 **\*Corresponding author:** Dr. Marisela Morales, Integrative Neuroscience Research Branch, National Institute on Drug  
18 Abuse, 251 Bayview Blvd., Baltimore, Maryland 21224, MMORALES@intra.nida.nih.gov

19  
20  
21 **Keywords:** VTA, VTA-VGluT2 neurons, VTA-GABA neurons, glutamate-GABA neurons, mu opioid receptors

22  
23  
24 **Impact Statement** (15-30 words). Some physiological properties of VTA glutamate-releasing and glutamate-GABA co-  
25 releasing neurons are distinct from those of VTA GABA-releasing neurons.  $\mu$ -opioid receptor activation hyperpolarizes  
26 some VTA glutamate-releasing and some GABA-releasing neurons.

27 **Abstract**

28 The ventral tegmental area (VTA) contains dopamine neurons intermixed with GABA-releasing (expressing vesicular  
29 GABA transporter, VGAT), glutamate-releasing (expressing vesicular glutamate transporter, VGluT2), and co-releasing  
30 (co-expressing VGAT and VGluT2) neurons. By delivering INTRSECT viral vectors into VTA of double *vglut2-*  
31 *Cre/vgat-Flp* transgenic mice, we targeted specific VTA cell populations for ex vivo recordings. We found that VGluT2<sup>+</sup>  
32 VGAT<sup>-</sup> and VGluT2<sup>+</sup> VGAT<sup>+</sup> neurons on average had relatively hyperpolarized resting membrane voltage, greater  
33 rheobase, and lower spontaneous firing frequency compared to VGluT2<sup>-</sup> VGAT<sup>+</sup> neurons, suggesting that VTA glutamate-  
34 releasing and glutamate-GABA co-releasing neurons require stronger excitatory drive to fire than GABA-releasing  
35 neurons. In addition, we detected expression of *Oprm1* mRNA (encoding  $\mu$  opioid receptors, MOR) in VGluT2<sup>+</sup> VGAT<sup>-</sup>  
36 and VGluT2<sup>-</sup> VGAT<sup>+</sup> neurons, and their hyperpolarization by the MOR agonist DAMGO. Collectively, we demonstrate  
37 the utility of the double transgenic mouse to access VTA glutamate, glutamate-GABA and GABA neurons, and show  
38 some electrophysiological heterogeneity among them.

## 39 Introduction

40 The ventral tegmental area (VTA) is a midbrain structure containing dopamine neurons that play a major role in motivated  
41 behaviors (Wise, 2004, Berridge et al., 2007, Bromberg-Martin et al., 2010). While it has classically been thought of as a  
42 dopaminergic structure, the VTA contains multiple types of neurons, including neurons that release GABA (expressing  
43 the synthesis enzyme glutamate decarboxylase, GAD, and the vesicular GABA transporter, VGaT) and neurons that  
44 release glutamate (expressing vesicular glutamate transporter type 2, VGluT2) (Yamaguchi et al., 2007). Moreover, we  
45 recently demonstrated that some VTA neurons release both glutamate and GABA (Root et al., 2014). These neurons  
46 express both VGluT2 and VGaT mRNA (VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons), whose proteins are distributed in separate pools of  
47 synaptic vesicles within a common axon terminal (Root et al., 2018). We have found a lateromedial gradient of  
48 distribution for VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons and those that release glutamate without GABA (VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons) or  
49 release GABA without glutamate (VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons) (Root et al., 2018).

50 The *ex vivo* electrophysiological properties of putative VTA dopamine neurons had been investigated for decades; the  
51 dopaminergic identification of VTA recorded neurons has been achieved by the immunocytochemical detection of  
52 tyrosine hydroxylase (TH) in rat (Margolis et al., 2006) or by *in vivo* labeling in transgenic mice (Khaliq & Bean, 2010).  
53 Characterization of VTA GABA neurons in *ex vivo* recordings has been achieved by GAD protein and mRNA detection  
54 in recorded neurons in rat (Margolis et al., 2012) or by *in vivo* labeling in transgenic mice with constitutive or viral vector-  
55 induced expression of green fluorescent protein (GFP) under the control of the GAD 2 (Tan et al., 2012) or VGaT (va  
56 Zessen et al., 2012) promoters. *Ex vivo* recordings of VTA glutamate neurons have been made in mice that constitutively  
57 express GFP under the control of the VGluT2 promoter (Hnasko et al., 2012). Importantly, these studies did not  
58 differentiate neurons that co-release glutamate and GABA (VGluT2<sup>+</sup> VGaT<sup>+</sup>) from those that are only glutamate-releasing  
59 (VGluT2<sup>+</sup> VGaT<sup>-</sup>) or GABA-releasing (VGluT2<sup>-</sup> VGaT<sup>+</sup>), raising the possibility that some of the overlapping  
60 physiological properties reported in these groups specifically belong to this co-releasing population.

61 While existing transgenic mice allow *in vivo* tagging of the entire population of VTA neurons expressing VGluT2 or  
62 VGaT, these transgenic lines are not suitable for the selective tagging of VGluT2<sup>+</sup> VGaT<sup>+</sup>, VGluT2<sup>+</sup> VGaT<sup>-</sup>, or VGluT2<sup>-</sup>  
63 VGaT<sup>+</sup> neurons. To overcome this limitation, we applied an intersectional approach to induce expression of enhanced  
64 YFP (eYFP) in the different classes of VTA neurons (Fenno et al., 2014). We found that some electrophysiological  
65 properties do vary across these different classes of VTA neurons, and determined that not only VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons,  
66 but also VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons, were postsynaptically inhibited by MOR activation.

## 67 Results

68 **Selective targeting of VTA VGluT2<sup>+</sup> VGaT<sup>+</sup>, VGluT2<sup>+</sup> VGaT<sup>-</sup> and VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons.** To tag VGluT2<sup>+</sup> VGaT<sup>+</sup>,  
69 VGluT2<sup>+</sup> VGaT<sup>-</sup>, and VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons, we generated *vglut2-Cre/vgat-Flp* mice by crossing *vglut2-Cre* mice  
70 with *vgat-Flp* mice (Figure 1A) and injected INTRSECT adeno associated viral (AAV) vectors into their VTA (Fenno  
71 et al., 2014). In different cohorts of *vglut2-Cre/vgat-Flp* mice, we injected AAV-C<sub>ON</sub>/F<sub>ON</sub>-eYFP vectors (requiring Cre  
72 and Flp recombinases for eYFP expression) to target VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons; AAV-C<sub>ON</sub>/F<sub>OFF</sub>-eYFP vectors  
73 (requiring the presence of Cre recombinase and absence of Flp recombinase for eYFP expression) to target VGluT2<sup>+</sup>  
74 VGaT<sup>-</sup> neurons; or AAV-C<sub>OFF</sub>/F<sub>ON</sub>-eYFP vectors (requiring the absence of Cre recombinase and presence of Flp  
75 recombinase for eYFP expression) to target VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons (Figure 1B-C).

76 After confirming VTA neuronal expression of eYFP in each cohort of mice (Figure 1D-F), we examined the  
77 mRNA expression of VGluT2 or VGaT within eYFP expressing neurons (Figure 1D-F). In the VTA of mice locally  
78 injected with AAV-C<sub>ON</sub>/F<sub>ON</sub>-eYFP vectors (to tag VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons) (Figure 1D), we found that within the  
79 total population of eYFP expressing neurons (1,647 neurons, 3 mice; Figure 1G), approximately 90% expressed both  
80 VGluT2 and VGaT mRNAs (87.3% ± 2.4%; 1,441/1,647); 6% expressed only VGluT2 mRNA (5.6% ± 1.6%; 88/1,647  
81 neurons), close to 5% expressed only VGaT mRNA (5.2% ± 2.0 %; 85/1,647, Figure 1G), and rarely lacked both  
82 VGluT2 and VGaT mRNAs (1.93% ± 0.35%; 33/1647). In the VTA of mice locally injected with AAV-C<sub>ON</sub>/F<sub>OFF</sub>-  
83 eYFP vectors (to tag VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons) (Figure 1E), we found that within the total population of eYFP  
84 neurons (2,804 neurons, 3 mice; Figure 1G) more than 90% expressed VGluT2 mRNA (93.1% ± 2.8%,  
85 2,563/2,804), none expressed VGaT mRNA alone, they rarely expressed VGluT2 mRNA together with VGaT mRNA  
86 (2.1% ± 0.9%, 76/2,804), and a small number lacked both VGluT2 or VGaT mRNAs (4.8% ± 2.0%, 165/2,804). In the  
87 VTA of mice locally injected with AAV-C<sub>OFF</sub>/F<sub>ON</sub>-eYFP vectors (to tag VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons) (Figure 1F), we  
88 found that within the total population of eYFP neurons, close to 85% expressed VGaT mRNA (84.7% ± 2.1%,  
89 1,904/2,228 neurons, 3 mice) (Figure 1F, G), rarely expressed VGluT2 mRNA (2.3% ± 1.1%, 41/2,228 neurons) (Figure  
90 1G), infrequently had VGaT mRNA together with VGluT2 mRNA (4.4% ± 1.4%; 91/2,228 neurons) (Figure 1G), and a  
91 small number lacked both VGluT2 and VGaT mRNAs (8.6% ± 0.5%, 192/2,228 neurons) (Figure 1G). Collectively,  
92 these findings indicate that using *vglut2-Cre/vgat-Flp* mice in combination with the tested INTRSECT viral vectors  
93 for the selective tagging of the three classes of VTA neurons generates very few false positive classifications.

94  
95 **Intrinsic properties of VTA VGluT2<sup>+</sup> VGaT<sup>+</sup>, VGluT2<sup>+</sup> VGaT<sup>-</sup> and VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons.** Next we determined  
96 the spontaneous action potential (AP) activity of the three classes of neurons with cell attached recordings in  
97 horizontal brain slices. We detected spontaneous activity in 46.2% of the VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons (24/52 neurons, 28  
98 mice), 52.6% of the VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons (24/49 neurons, 27 mice) and 70.7% of the VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons  
99 (29/41 neurons, 19 mice) (Figure 2C). Within the spontaneously active neurons (77 neurons), we found that the mean  
100 firing frequency was lower in VGluT2<sup>+</sup> VGaT<sup>+</sup> and VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons than in VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons (3.4 ±  
101 0.7 Hz for VGluT2<sup>+</sup> VGaT<sup>+</sup>, n= 24 neurons, 20 mice; 3.5 ± 0.7 Hz for VGluT2<sup>+</sup> VGaT<sup>-</sup>, n= 24 neurons, 18 mice; and  
102 8.3 ± 2.1 Hz for VGluT2<sup>-</sup> VGaT<sup>+</sup> n= 29 neurons, 14 mice) (Figure 2B, D). Together these findings indicate that more  
103 VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons fire spontaneously, and on average they fire faster, than VGluT2<sup>+</sup> VGaT<sup>+</sup> or VGluT2<sup>+</sup> VGaT<sup>-</sup>  
104 neurons. Next, we analyzed the extracellular AP durations from these neurons and found that VGluT2<sup>+</sup> VGaT<sup>+</sup>  
105 neurons have similar AP durations to VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons, and both of these phenotypes have shorter AP  
106 durations than VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons (1.3 ± 0.1 ms for VGluT2<sup>+</sup> VGaT<sup>+</sup>, n= 24 neurons, 20 mice; 1.7 ± 0.1 ms for  
107 VGluT2<sup>+</sup> VGaT<sup>-</sup>, n= 24 neurons, 18 mice; and 1.2 ± 0.1 ms for VGluT2<sup>-</sup> VGaT<sup>+</sup> n= 29 neurons, 14 mice) (Figure  
108 2F,G). Because VTA neurons are known to have pacemaker activity as well as burst firing patterns, we also evaluated  
109 the regularity of firing. We analyzed the coefficient of variation (CV) of inter-spike intervals (ISIs), and found that  
110 both VGluT2<sup>+</sup> VGaT<sup>+</sup> and VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons had higher CVs of ISIs compared to VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons  
111 (48.5 ± 6.00 for VGluT2<sup>+</sup> VGaT<sup>+</sup>, 41.8 ± 6.5 for VGluT2<sup>+</sup> VGaT<sup>-</sup>, and 37.2 ± 4.9 for VGluT2<sup>-</sup> VGaT<sup>+</sup>) (Figure 2E).  
112 These findings indicate that the spontaneous firing of VGluT2<sup>+</sup> VGaT<sup>+</sup> and VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons is more irregular  
113 than that of VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons.

114 Next, using whole-cell recordings, we examined intrinsic electrophysiological properties of these three classes of  
115 VTA neurons. We found that the resting membrane potential was -68.0 ± 1.2 mV for VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons (n= 52  
116 neurons, 27 mice), -64.6 ± 0.9 mV for VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons (n= 49 neurons, 27 mice), and -59.6 ± 0.9 mV for  
117 VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons (n= 41 neurons, 19 mice). We detected the greatest rheobase in VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons  
118 (37.3 ± 5.6 pA, n= 48 neurons, 27 mice), followed by VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons (29.0 ± 5.5 pA, n= 52 neurons, 28 mice),

119 and the lowest rheobase in VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons ( $14.9 \pm 2.9$  pA,  $n = 41$ , 19 mice) (Table 1). Collectively these  
120 findings indicate that VTA neurons expressing VGluT2, with or without VGaT, are less excitable than VTA neurons  
121 lacking VGluT2, and the VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons are the least excitable among the 3 classes. Across the three classes  
122 of VTA neurons, there were no differences in membrane capacitance, membrane resistance, membrane time constant,  
123 or AP threshold. However, in line with our cell attached data, we found that VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons have longer  
124 duration APs than VGluT2<sup>+</sup> VGaT<sup>+</sup> and VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons ( $2.2 \pm 0.1$  ms for VGluT2<sup>+</sup> VGaT<sup>+</sup>,  $n = 52$  neurons,  
125 mice;  $2.9 \pm 0.2$  ms for VGluT2<sup>+</sup> VGaT<sup>-</sup>,  $n = 48$  neurons, 27 mice and  $1.8 \pm 0.1$  ms for VGluT2<sup>-</sup> VGaT<sup>+</sup>,  $n = 41$  neurons, 19  
126 mice) (Table 1).

127 Given that hyperpolarization-activated cation currents ( $I_h$ ) are present in both dopamine and non-dopamine neurons  
128 (Jones and Kauer, 1999; Margolis et al., 2006; Margolis et al., 2012; Hnasko et al., 2012), we tested the three classes of  
129 VTA neurons for  $I_h$ . We detected  $I_h$  in 46.2% of VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons (24/52 neurons, 28 mice), 53.3% of  
130 VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons (24/45 neurons from 24 mice) and 92% of VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons (35/38 neurons, 18 mice)  
131 (Figure 3B). While there was a wide range of  $I_h$  magnitude among each cell type, the mean  $I_h$  magnitude was smaller  
132 in VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons compared to VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons or VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons ( $22.4 \pm 3.2$  pA for  
133 VGluT2<sup>+</sup> VGaT<sup>+</sup>,  $56.8 \pm 12.2$  pA for VGluT2<sup>+</sup> VGaT<sup>-</sup>, and  $48.3 \pm 8.7$  pA for VGluT2<sup>-</sup> VGaT<sup>+</sup>) (Figure 3A, C). We  
134 found that regardless of the neuronal cell type, the neurons with larger  $I_h$  magnitudes were located in the lateral VTA  
135 and those with low amplitudes were in the medial VTA. These findings support a VTA latero-medial neuronal  
136 topography among dopamine and non-dopamine neurons.

137  
138 **Stimulated firing patterns of VTA VGluT2<sup>+</sup> VGaT<sup>+</sup>, VGluT2<sup>+</sup> VGaT<sup>-</sup> and VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons.** We next  
139 examined the stimulated firing patterns of these three classes of neurons by inducing AP firing in current clamp with a  
140 series of depolarizing current steps (500 ms, 10-150 pA).

141 We found that most VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons (41/48 neurons, 24 mice) fired APs with short latency from initiation of  
142 the current pulse ( $159 \pm 14$  ms; Figure 4A-B, D). A small group of neurons responded to the injected current with  
143 delayed firing (7/48 neurons, 6 mice;  $383 \pm 47$  ms; Figure 4A-B, D), displaying a slow depolarizing ramp prior to the first  
144 AP (Figure 4A). We found that the rheobase was generally greater in VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons with long latency ( $101.4 \pm$   
145  $24.8$  pA) than in those with short latency ( $17.8 \pm 2.5$  pA; Figure 4C). We observed that current injections below 100 pA  
146 produced depolarization block in some of the short latency neurons (14/41 neurons, 8 mice; Figure 4D). Across all short  
147 latency VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons (41 neurons), more than half of them fired APs continuously during the entire current  
148 injection (27/41 neurons, 18 mice; Figure 4D). Furthermore, many of these neurons with continuous AP firing showed  
149 frequency adaptation (being more evident at currents above 100 pA; 18/27 neurons, 12 mice; Figure 4D), with the ISI  
150 increasing after each AP (Figure 4-figure supplement 1), but others either lacked or had minimal frequency adaptation  
151 (9/27 neurons, 7 mice; Figure 4-figure supplement 1) that permitted higher firing rates ( $38.7 \pm 3.2$  Hz sustained firing with  
152 adaptation;  $84.2 \pm 5.7$  Hz for sustained firing without adaptation). VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons were similar to VGluT2<sup>+</sup>  
153 VGaT<sup>+</sup> neurons, with short latency AP firing in response to injected current (29/45 neurons, 22 mice;  $122 \pm 16$  ms  
154 latency) and fewer long latency responses with a depolarizing ramp leading to firing (16/45 neurons, 13 mice;  $462 \pm 11$   
155 ms latency; Figure 4A-B, D). Among the neurons with depolarizing ramp responses (VGluT2<sup>+</sup> VGaT<sup>+</sup> and VGluT2<sup>+</sup>  
156 VGaT<sup>-</sup> neurons), we detected A-type K<sup>+</sup> currents ( $I_A$ ), which were blocked by the  $I_A$  blocker 4-Aminopyridine (4-AP; 2  
157 mM) (Figure 4-figure supplement 2A-B). In addition, we found that 4-AP application decreased AP firing latency (4  
158 VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons and 4 VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons, 8 mice; Baseline =  $458 \pm 7$  ms, 4-AP =  $192 \pm 29$  ms; Figure 4-  
159 figure supplement 2F), and increased the total number of APs fired during an input/output curve (10-150 pA, 500 ms) (4  
160 VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons and 4 VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons, 8 mice; Baseline =  $52.6 \pm 17.8$ , 4-AP =  $101 \pm 24.3$ ; Figure 4-  
161 figure supplement 2 C, G). Compared to any neurons expressing VGluT2 (VGaT<sup>+</sup> or VGaT<sup>-</sup>), we found that all recorded  
162 VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons had short latency AP firing responses to injected depolarizing current steps (38 neurons, 18  
163 mice,  $127.7 \pm 13.5$  ms latency; Figure 4A-B, D), and a subset showed frequency adaptation (22/38 neurons, 15 mice)  
164 (Figure 4D). Collectively, these results demonstrate that both glutamate-GABA co-releasing (VGluT2<sup>+</sup> VGaT<sup>+</sup>) and  
165 glutamate-releasing (VGluT2<sup>+</sup> VGaT<sup>-</sup>) neurons are more heterogeneous in their firing properties than GABA-releasing  
166 (VGluT2<sup>-</sup> VGaT<sup>+</sup>) neurons.

167 Given that previous studies have shown hyperpolarization-induced rebound burst firing in a subset of VTA dopamine  
168 and non-dopamine neurons mediated by  $I_h$  (Tateno and Robinson, 2011) or T-type calcium channels (Tracy et al., 2018,  
169 Woodward et al., 2019), we next tested the extent to which rebound firing occurs in the three classes of VTA neurons.  
170 After holding the resting membrane potential at -100 mV for 1 sec and then releasing that clamp, approximately 25% of



VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons showed rebound firing with short bursts of 2-4 APs (12/48 neurons, 10 mice; Figure 5), and this response was stable over repeated trials (Figure 5-supplement figure 1). In some of these neurons we tested if *I<sub>h</sub>* blocker ZD 7288 stopped rebound firing, and found that it did in 2/4 neurons. In a different set of neurons we tested if mibefradil blocked the rebound firing, and found that it did in 3/5 neurons by the *I<sub>h</sub>* blocker ZD 7288 (2/4 tested neurons) while in others it was blocked by T-type calcium channel blocker (Mibefradil; 3/5 tested neurons). Furthermore, we observed that 35% of VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons (16/45 neurons, 11 mice) had rebound firing that was blocked by ZD 7288 (7/7 tested neurons) or Mibefradil (2/4 tested neurons) (Figure 5). In contrast, we found that half (20/38 neurons, 14 mice) of the VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons showed rebound firing, which was blocked by ZD 7288 (5/6 tested neurons) or Mibefradil (2/5 tested neurons) (Figure 5). These findings demonstrated that some of the glutamate-GABA co-releasing neurons, glutamate-releasing and GABA-releasing neurons have rebound firing mediated by either *I<sub>h</sub>* or T-type calcium channels.

**VTA neuronal clustering by electrophysiological properties.** We next evaluated the extent to which the electrophysiological properties described above grouped together by applying a cluster analysis based on K-mean clustering and similarity parametric (Pearson's correlation coefficient) on data obtained from the firing properties and intrinsic properties (Figure 6A). Based on the cluster analysis, we found 4 clusters of neurons with distinctive firing features, but these clusters did not uniquely correspond to any of our three neurotransmitter phenotypes (Figure 6B). For the 131 clustered neurons, 36.6% (48/131 neurons, 33 mice) grouped in cluster 1, 32.1% (42/131 neurons, 31 mice) in cluster 2, 13.7% (18/131 neurons, 11 mice) in cluster 3, and 17.6% (23/131 neurons, 20 mice) in cluster 4 (Figure 6B).

In cluster 1 (48 neurons), 39.5% were VGluT2<sup>+</sup> VGaT<sup>+</sup> (19/48 neurons, 12 mice), 18.8% were VGluT2<sup>+</sup> VGaT<sup>-</sup> (9/48 neurons, 7 mice), and 41.6% were VGluT2<sup>-</sup> VGaT<sup>+</sup> (20/48 neurons, 15 mice) (Figure 6B). Neurons grouped within the cluster 1 were characterized by a sustained AP firing with marked adaptation (46.5 ± 2.8 Hz maximal AP frequency, Figure 5H), and depolarized membrane potential (-61.9 ± 0.8 mV; Figure 6E). We found that 75% of the neurons within this cluster were spontaneously active during cell attached recordings (36/48 neurons, 29 mice), representing the highest percentage of spontaneously active neurons among the four different clusters. In cluster 2, 21.4% were VGluT2<sup>+</sup> VGaT<sup>+</sup> (9/42 neurons, 8 mice), 35.7% were VGluT2<sup>+</sup> VGaT<sup>-</sup> (15 /42 neurons, 12 mice), and 42.8% were VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons (18/42 neurons, 12 mice) (Figure 6B). The neurons in this cluster had small rheobase (11.6 ± 1.4 pA; Figure 6F), short latency AP firing in response to depolarizing current steps (97 ± 10 ms Figure 6G), and sustained firing with minimal frequency adaptation in response to current steps (76.1 ± 3.4 Hz; Figure 6H). We found that 69% (29 /42 neurons, 23 mice) of the neurons in this cluster showed rebound firing after release from clamp induced hyperpolarization. In cluster 3, 72.2% were VGluT2<sup>+</sup> VGaT<sup>+</sup> (13/18 neurons, 8 mice) and 27.8% were VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons (5/18 neurons, 4 mice; Figure 6B). Neurons grouped in this cluster exhibited rapid depolarization block during low magnitude depolarizing current steps (Figure 6C, D). In cluster 4, 30.4% (5/23 neurons from 5 mice) were VGluT2<sup>+</sup> VGaT<sup>+</sup> and 69.5% were VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons (16 /23 neurons, 14 mice). No VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons were classified to this cluster. Neurons in cluster 4 had larger rheobase (83.9 ± 11.1 pA; Figure 6F), long latencies to AP firing in response to injected current steps (452 ± 11 ms; Figure 6G), a depolarizing ramp before the onset of AP firing during current steps (Figure 6C-E), and included some neurons with *I<sub>A</sub>* (Supplementary Figure 2C-G). We found that all neurons within cluster 4 were quiescent during cell attached recordings.

Next, we determined whether the 4 identified clusters of physiological properties had specific topography within the VTA by mapping the distribution of neurons that we filled with biocytin after recordings. We found cluster 1 neurons in ventral and middle VTA, with a dorsal to ventral, and lateral to medial increasing gradient of distribution (Figure 7B). We frequently observed cluster 2 neurons in middle VTA concentrated more medially (Figure 7C), cluster 3 neurons in the ventral and middle VTA also enriched medially (Figure 7D) and cluster 4 neurons in the middle and dorsal VTA confined to the most medial part of the VTA (Figure 7E). These findings indicate that VGluT2<sup>+</sup> VGaT<sup>+</sup>, VGluT2<sup>+</sup> VGaT<sup>-</sup> and VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons have a topographic organization more related to shared electrophysiological properties rather than to the neurotransmitter that they release.

**μ-opioid receptors (MORs) are present in VTA GABA-releasing and glutamate-releasing neurons.** Given that previous electrophysiological studies have demonstrated the presence of MORs in a subset of VTA GABA releasing neurons (Margolis et al., 2012), and anatomical studies have documented expression of *Oprm1* mRNA in VTA VGluT2 neurons (Kudo et al., 2014), we systematically analyzed *Oprm1* mRNA expression in VTA neurons that express VGluT2 mRNA and VGaT mRNA. We detected *Oprm1* mRNA in VGluT2<sup>+</sup> VGaT<sup>-</sup> (Figure 8A), VGluT2<sup>-</sup> VGaT<sup>+</sup>

223 (Figure 8B) and VGlut2<sup>+</sup> VGaT<sup>+</sup> neurons in coronal mouse sections (Figure 8C). We determined that within the total  
224 population of VTA neurons expressing Oprm1 mRNA (1,718 neurons, 3 mice), almost 20% expressed VGlut2  
225 mRNA without VGaT mRNA (19.45% ± 0.9%; 336/1,718 neurons), 78% expressed VGaT mRNA without VGlut2  
226 mRNA (78% ± 0.9%; 1,337/1,718 neurons), and a small number co-expressed VGlut2 mRNA and VGaT mRNA  
227 (2.5% ± 0.2%; 43/1,718 neurons) (Figure 8D). These findings demonstrated that GABA-releasing and glutamate-  
228 releasing neurons are two major classes of VTA neurons with the capability to synthesize MORs.

229 Next, we tested both VGlut2<sup>+</sup> VGaT<sup>-</sup> and VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons for responses to the MOR selective agonist  
230 DAMGO (1μM). We detected DAMGO induced hyperpolarizations in a subset of VGlut2<sup>+</sup> VGaT<sup>-</sup> neurons (-7.1 ± 1.7  
231 mV; -64.3 ± 2.7 mV baseline, -71.4 ± 3.2 mV DAMGO, n = 7 out of 17 tested neurons, 14 mice) (Figure 7 F-G).  
232 Hyperpolarizations were also observed in the presence of the GABA<sub>A</sub> receptor antagonist (Bicuculline, 10μM) (Figure 8-  
233 supplement figure 1). Application of the MOR selective antagonist CTAP (1μM) reversed the DAMGO-induced  
234 hyperpolarizations (-73.3 ± 3.1 mV baseline, -84.5 ± 2.7 mV DAMGO, -72.5 ± 3.4 mV for DAMGO + CTAP, 5 tested  
235 neurons) (Figure 7 H-I). Similarly, we detected DAMGO induced hyperpolarizations in just over half of VGlut2<sup>-</sup> VGaT<sup>+</sup>  
236 tested neurons (-7.7 ± 1.3 mV; -64.1 ± 1.9 mV baseline, -71.8 ± 2.1 mV DAMGO, n = 10 out of 18 tested neurons, 15  
237 mice) (Figure 7 F-G), and these were also reversed by CTAP (-58.9 ± 1.0 baseline, -64.9 ± 1.2 DAMGO, -60.5 ± 1.2  
238 DAMGO + CTAP, 6 tested neurons) (Figure 7 H-I). Collectively, these findings indicate that a subset of VTA neurons  
239 that release either GABA or glutamate express functional MOR in their somatodendritic region, the activation of which  
240 results in their hyperpolarization.

## Discussion

The VTA has historically been considered a dopamine brain structure, and the properties of these dopamine neurons have been intensively investigated for decades. However, the VTA has three additional major classes of neurons: GABA-releasing (VGluT2<sup>-</sup>VGaT<sup>+</sup>), glutamate-releasing (VGluT2<sup>+</sup>VGaT<sup>-</sup>) and glutamate-GABA co-releasing (VGluT2<sup>+</sup>VGaT<sup>+</sup>) neurons, whose physiological properties were unclear. To specifically study these three classes of neurons, we selectively tagged each class by *in vivo* expression of eYFP after intra-VTA delivery of INTRSECT viral vectors (C<sub>ON</sub>/F<sub>ON</sub>, C<sub>ON</sub>/F<sub>OFF</sub> or C<sub>OFF</sub>/F<sub>ON</sub>) in different cohorts of double transgenic *vglut2-Cre/vgat-Flp* mice. We validated the selective expression of eYFP in each of the three targeted classes of VTA neurons by demonstrating that: (1) most of the VTA transduced neurons with C<sub>ON</sub>/F<sub>ON</sub> viral vector (for targeting glutamate-GABA co-releasing neurons) co-expressed VGluT2 and VGaT mRNAs, (2) those transduced with C<sub>ON</sub>/F<sub>OFF</sub> viral vector (for targeting glutamate-releasing neurons) expressed VGluT2 mRNA without VGaT mRNA, and (3) those transduced with C<sub>OFF</sub>/F<sub>ON</sub> viral vector (for targeting GABA-releasing neurons) expressed VGaT mRNA without VGluT2 mRNA. Using *ex vivo* VTA recordings of the three classes of transfected neurons, we found that both glutamate-releasing and glutamate-GABA co-releasing neurons have lower excitability and lower basal firing activity than GABA-releasing neurons. In addition, while we observed diversity in the depolarization-induced firing patterns of glutamate-releasing and glutamate-GABA co-releasing neurons, the responses among GABA-releasing neurons were more uniform. We also demonstrated that whereas most of the VTA neurons containing the  $\mu$  opioid receptors (MORs) are GABA-releasing neurons, 40% of glutamate-releasing neurons were also hyperpolarized by MOR activation. Collectively, we provide evidence that: (1) the VTA neuronal firing of both glutamate-releasing and glutamate-GABA co-releasing neurons require a stronger excitatory input to fire than GABA-releasing neurons, (2) the ionic channel composition is likely to be more diverse among glutamate-releasing and glutamate-GABA co-releasing neurons than among GABA-releasing neurons, and (3) postsynaptic MOR activation inhibits the activity of both GABA-releasing and glutamate-releasing VTA neurons.

It is well documented that  $I_h$  is present in both dopamine and non-dopamine neurons (Jones and Kauer, 1999; Margolis et al., 2006), including neurons expressing GAD (Chieng et al., 2011; Margolis et al., 2012; Ntamati et al., 2018), VGaT (Woodward et al., 2019) or VGluT2 (Hnasko et al., 2012). We extended these observations by showing that  $I_h$  is present in less than half of the glutamate-GABA co-releasing neurons, about half of the glutamate-releasing neurons and in more than 90% of the GABA-releasing neurons. However, the mean  $I_h$  magnitude is smallest in glutamate-GABA co-releasing neurons, followed by GABA-releasing neurons, and largest in glutamate-releasing neurons. We found that regardless of the neuronal cell type, the neurons with the greatest  $I_h$  magnitudes were located in the lateral VTA, and those with low amplitudes were in the medial VTA. These findings are consistent with the VTA latero-medial neuronal heterogeneity observed in dopamine neurons (Li X et al., 2013, Morales and Margolis 2017) and show it is a property shared by all classes of VTA neurons. While the molecular bases underlying differences in  $I_h$  magnitude among VTA neurons remains to be determined, one possibility is differential levels of expression of any of the four hyperpolarization-activated cyclic nucleotide-gated channel (HCN1-4) subunits that generate  $I_h$  and whose transcripts have been detected in the VTA (Monteggia et al., 2000). As an alternative, differences in  $I_h$  magnitude may reflect differential neuronal distribution of the HCN channels across neuronal compartments, as the HCN subunits have been detected in the plasma membrane of cell bodies, dendrites, or axons (Notomi and Shigemoto, 2004).

While our findings on the intrinsic properties of VTA neurons suggest that stronger excitatory drive is required for firing in VTA glutamate-releasing and glutamate-GABA co-releasing neurons compared to VTA GABA-releasing neurons, it remains to be determined which glutamatergic sources target each class of VTA neuron. Ultrastructural and electrophysiological reports indicate that VTA neurons expressing either GAD or VGaT receive excitatory input from different brain areas. For instance, pioneer ultrastructural studies showed that VTA GABA-neurons (expressing GAD) receive asymmetric (excitatory-type) synapses from axon terminals whose neurons originate in the lateral habenula (Olmelchenko et al., 2009), medial prefrontal cortex (Carr and Sesack, 2000), periaqueductal grey (Olmelchenko and Sesack, 2010), and bed nucleus of the stria terminalis (Kudo et al., 2012). Furthermore, recent findings utilizing optogenetics and VTA slice electrophysiology have shown that the firing of GABA neurons (expressing VGaT or GAD) is evoked by exciting glutamatergic inputs (expressing VGluT2) from lateral hypothalamus neurons (Nieh et al., 2015), superior colliculus neurons (Zhou et al., 2019) or periaqueductal grey neurons (Ntamati et al., 2018). Moreover, a circuitry-based study on input from the periaqueductal grey to VTA showed that periaqueductal glutamatergic neurons preferentially target the GAD neurons with large  $I_h$  (Ntamati et al., 2018). Though it is possible that some of the GABA neurons identified in these prior studies were in fact glutamate-GABA co-releasing neurons, information on glutamatergic afferents to VTA glutamatergic neurons is limited. We recently reported quantitative ultrastructural,



293 optogenetic, and electrophysiological evidence that VTA glutamate-releasing neurons (VGluT2<sup>+</sup> VGaT<sup>-</sup>) receive a strong  
294 glutamatergic input from the lateral hypothalamic area, LHA (Barbano et al., 2020). Furthermore, we also showed that the  
295 somatodendritic region of a single VTA glutamate-releasing neuron receives multiple asymmetric synapses from axon  
296 terminals arising from LHA glutamatergic neurons (Barbano et al., 2020). Thus, these observations underscore the  
297 importance that characterization of the precise synaptic organization between different classes of VTA neuronal types and  
298 specific afferents, from neurons of the same nature and shared brain structure, provides on achieving a better  
299 understanding on the firing regulation of diverse classes of VTA neurons.

300 Previous studies found hyperpolarization-induced rebound burst firing in subsets of VTA dopamine and non-  
301 dopamine neurons mediated by  $I_h$  (Tateno and Robinson, 2011) or T-type calcium channels (Tracy et al., 2018,  
302 Woodward et al., 2019). We found the same types of responses in subpopulations of glutamate-GABA co-releasing,  
303 glutamate-releasing and GABA-releasing neurons. A recent VTA electrophysiological study in a VGaT Knock-in rat line  
304 expressing the fluorescent protein Venus reported two populations with different rebound firing properties (type 1 with  
305 low threshold calcium spikes during rebound firing, and type two with post hyperpolarizing action potentials during  
306 rebound firing) of VGaT-Venus neurons expressing T-channels (Woodward et al., 2019). Given that we detected T-  
307 channel mediated rebound in glutamate-GABA co-releasing and GABA-releasing neurons, and both classes of neurons  
308 express VGaT (Root et al., 2018b), it remains to be determined the extent to which these two classes of neurons  
309 overlapped with those detected in rat VTA VGaT-Venus neurons.

310 Findings from electrophysiological and pharmacological studies show presynaptic and postsynaptic MOR function in  
311 the VTA (Johnson and North 1992, Margolis et al., 2012; Fields and Margolis, 2015). While postsynaptic MORs are  
312 generally thought to be limited to GABA neurons within the VTA, we observed transcripts encoding MORs (Oprm1)  
313 expressed in a subset of glutamate-releasing neurons, and these neurons were clustered in the midline aspects of the VTA.  
314 We also found that MOR activation hyperpolarizes these glutamate-releasing neurons. These findings of postsynaptic  
315 actions of MORs within two subpopulations of VTA neurons together with the presence of MORs in synaptic terminals  
316 (Margolis et al., 2004, Zhang et al., 2015, Chen et al., 2015, Bull et al., 2017) underscore the complex actions of opioids  
317 within the VTA.

318 In summary, we detected unique as well as overlapping electrophysiological properties among the glutamate-GABA  
319 co-releasing, glutamate-releasing and GABA-releasing VTA neurons. Our electrophysiological findings indicate that  
320 firing of VTA glutamate-GABA co-releasing and glutamate-releasing neurons may require stronger excitatory drive  
321 compared to the GABA-releasing neurons. However, given that the neuronal firing pattern depends on both  
322 the intrinsic properties of the neurons and the network activity innervating them, future studies are necessary to identify  
323 the origin, nature, and impact of inputs to the specific classes of VTA neurons.

## 324 **Materials and Methods**

### 325 **Experimental subjects:**

326 Both male and female mice were used in this study. The *vglut2-IRES::Cre* mice (JAX # 016963) and *vgat::FlpO* mice  
327 (JAX # 031331; Daigle et al., 2018) were crossed to produce a *vglut2-IRES::Cre x vgat::FlpO* mice. Animals were  
328 housed in temperature- and humidity-controlled facilities under a 12 h light/dark cycle with dawn at 0700 h and ad libitum  
329 chow and water prior to the start of experimental procedures. Mice were 2-3 months of age at the start of the experiment.  
330 Experiments were conducted in accordance with the USPHS Guide for the Care and Use of Laboratory Animals and  
331 approved by the Animal Care and Use Committee of the National Institute on Drug Abuse Intramural Research Program.  
332

### 333 **Surgery and Virus Injections:**

334 Mice were anesthetized with isoflurane (2-4% induction; 1% maintenance) and secured to a stereotaxic frame. After  
335 exposing the top of the skull, the mouse's head was leveled to ensure the skull was flat. One of the following 3 viruses  
336 were injected into the VTA (0.3  $\mu$ l; AP: -3.1 to -3.3, ML:  $\pm$  0.0, DV: -4.3 to -4.4) to label the different classes of VTA  
337 neurons: (1) AAV5-Hsyn-C<sub>ON</sub>-F<sub>ON</sub>-eYFP to label VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons, (2) AAV5-Hsyn-C<sub>ON</sub>-F<sub>OFF</sub>-eYFP to label  
338 VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons or (3) AAV5-Hsyn-C<sub>OFF</sub>-F<sub>ON</sub>-eYFP to label VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons. Injections were made  
339 using a Micro4 controller and UltraMicroPump along with 10  $\mu$ l Nanofil syringes equipped with 35-gauge needles (WPI  
340 Inc., Sarasota, FL). Syringes were left in place for 10 min following injections to minimize diffusion. Following surgery,  
341 mice recovered on a warm heating pad before being transferred back to the vivarium home cage. Mice remained in the  
342 colony to allow for recovery and virus expression for 6-8 weeks for RNAscope experiments and 4-6 weeks prior  
343 electrophysiology experiments.

### 344 **Combination of RNAscope *in situ* Hybridization and Immunolabeling**

345 Tissue preparation: *Wild-type* mice and *Vglut2-IRES::Cre x Vgat::FlpO* mice of six to eight weeks following virus  
346 injections were anesthetized with chloral hydrate (0.5 ml/kg) and perfused transcardially with 4% (w/v) paraformaldehyde  
347 (PF) in 0.1 M phosphate buffer (PB), pH 7.3. Brains were left in 4% PF for 2 h and transferred to 18% sucrose in PB  
348 overnight at 4°C to prepare them for RNAscope *in situ* hybridization-immunohistochemistry experiments. The detection  
349 of transcripts encoding VGluT2 mRNA, VGaT mRNA and Oprm1 mRNA were done by using RNAscope, and TH  
350 detection by immunohistochemistry. Coronal free-floating sections (wild-type mouse, VTA, 16  $\mu$ m) were incubated for 2  
351 h at 30°C with Mouse anti-TH antibody (1:1000, MAB318, Millipore, Burlington, MA) in DEPC-treated phosphate buffer  
352 (PB) with 0.5% Triton X-100 supplemented with RNasin (Promega, Madison, WI). Sections were rinsed 3  $\times$  10 min with  
353 DEPC-treated PB, and incubated with secondary Donkey anti-Mouse Alexa Fluor 750 (1:100, ab175738, abcam,  
354 Cambridge, MA) for 1 h at 30°C. Sections were rinsed with DEPC-treated PB and then were mounted onto Fisher  
355 SuperFrost slides and dried overnight at 60°C. RNAscope *in situ* hybridization processing was performed in accordance to  
356 the manufacturer's instructions (Advanced Cell Diagnostics, Newark, CA). Briefly, sections were treated with heat and  
357 protease digestion followed by hybridization with a mixture containing target probes to mouse VGluT2 (319171), VGaT  
358 (319191-C3) and Oprm1 (489311-C2). Additional sections were hybridized with the bacterial gene DapB as a negative  
359 control, which did not exhibit fluorescent labeling. VGluT2 were detected by Atto 550, VGaT were detected by Alexa  
360 488, and Oprm1 were detected by Atto 647. GFP immunolabeling and detection of mRNA for VGluT2 and VGaT were  
361 performed as described above. VTA Coronal free-floating sections (*VGluT2-Cre x VGaT-FlpO* mouse, 16  $\mu$ m in  
362 thickness) were processed for immunodetection of Mouse anti-GFP antibody (1:500, 632381, Takara Bio USA, Inc.  
363 Mountain View, CA) and incubated with secondary Donkey anti-Mouse Alexa Fluor 488 (1:100, 715-545-151, Jackson  
364 ImmunoResearch, West Grove, PA), after processing by RNAscope *in situ* hybridization, VGluT2 were detected by Atto  
365 550, VGaT were detected by Atto 647. RNAscope *in situ* hybridization sections were viewed, analyzed, and photographed  
366 with an Olympus FV1000 confocal microscope or a Keyence BZ-X800 microscope. Negative control hybridizations  
367 showed negligible fluorophore expression. Neurons were counted when the stained cell was at least 5  $\mu$ m in diameter.  
368 Pictures were adjusted to match contrast and brightness by using Adobe Photoshop (Adobe Systems). The number of mice  
369 (n=3/group; 13-16 sections/mouse) analyzed was based on previous studies in our lab using radioactive detection of  
370 VGluT2 mRNA from rat VTA neurons.

### 371 **Patch-clamp recordings:**

372 Six to eight weeks after virus injection, mice were anesthetized with isoflurane, decapitated, and the brain was quickly  
373 removed and placed in ice-cold artificial cerebrospinal fluid (ACSF), saturated with 95% O<sub>2</sub> and 5% CO<sub>2</sub>, and modified to  
374 contain (in mM): 92 NMDG, 20 HEPES, 25 glucose, 30 NaHCO<sub>3</sub>, 1.2 NaH<sub>2</sub>PO<sub>4</sub>, 2.5 KCl, 5 sodium ascorbate, 3 sodium  
375 pyruvate, 2 thiourea, 10 MgSO<sub>4</sub>, 0.5 CaCl<sub>2</sub> on a VT-1200 vibratome (Leica, Nussloch, Germany), and sectioned through  
376 the VTA in horizontal slices (200 μm thick). The slices were placed in a holding chamber filled with the same solution but  
377 held at 32°C. After 10-15 minutes, slices were transferred to a holding chamber containing room temperature ACSF  
378 modified to contain (in mM): 92 NaCl, 20 HEPES, 25 glucose, 30 NaHCO<sub>3</sub>, 1.2 NaH<sub>2</sub>PO<sub>4</sub>, 2.5 KCl, 5 sodium ascorbate, 3  
379 sodium pyruvate, 2 thiourea, 1 MgSO<sub>4</sub>, 2 CaCl<sub>2</sub>. For recordings, slices were transferred to a chamber superfused with  
380 32°C ACSF containing (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 1 MgCl<sub>2</sub>, 2.4 CaCl<sub>2</sub>, 26 NaHCO<sub>3</sub>, and 11 glucose.  
381 Electrodes (2-4MΩ) were backfilled with an internal solution containing (in mM): 120 potassium gluconate, 8.0 NaCl, 1.0  
382 MgCl<sub>2</sub>, 10 HEPES, 2.0 Mg-ATP, 0.3 Na<sub>2</sub>-GTP, 10 ditris-phosphocreatine, 0.2 EGTA and 0.2% biocytin (pH 7.2; 275-290  
383 mOsm). Cells were visualized on an upright microscope using infrared differential interference contrast video  
384 microscopy. Whole-cell voltage clamped, and current clamped recordings were made using a MultiClamp 700B amplifier  
385 (2 kHz low-pass Bessel filter and 10 kHz digitization) with pClamp 10.3 software (Molecular Devices, Sunnyvale, CA).  
386 Firing rate was determined before breaking into the cell under cell attached mode for at least 60 seconds of continuous  
387 activity. *I<sub>h</sub>* was measured under voltage clamp mode holding at -60 mV and stepping to -120, -100, and -80 mV for 1000  
388 ms. Membrane potential and AP properties were measured in current clamp *I*=0 within the first 5 minutes after gaining  
389 whole cell access. To determine excitability and firing properties, an input/output curve consisting of depolarizing current  
390 steps of 500 ms duration from 0-150 pA were applied and the number of APs fired during each current step were  
391 quantified with pClamp 10.1 software. To determine adaptation of AP firing, ISI of the first 10 AP fired after current  
392 injection able to evoke the maximum response was analyzed. Neurons with an increase of more than 50% of the ISI  
393 during the first 10 AP was classified as neuron with adaptation. *I<sub>A</sub>* current was measured in voltage clamp using two step  
394 protocol. The first step consisted of a 500 ms hyperpolarizing pre-pulse (-120 mV, 500 ms) followed by increasing  
395 depolarizing steps from -100 mV to 30 mV for 1000 ms. The second step was a depolarizing pre-pulse (40 mV) followed  
396 by depolarizing steps from -100 mV to 30 mV 1000 ms. *I<sub>A</sub>* was obtained by subtracting the currents generated by the  
397 second protocol from the currents generated by the first protocol. In the current clamp recordings where *I<sub>A</sub>* was blocked by  
398 4-AP, the membrane potential of the cell was clamped in the membrane potential before the addition of 4-AP and CNQX  
399 was applied to prevent an increase AP firing due to an increase in glutamatergic transmission.

#### 400 Cluster analysis

401 Cluster analysis was applied to data from 131 VTA neurons using 21 electrophysiological parameters that include:  
402 membrane potential, membrane capacitance, membrane resistance, time constant, tonic firing frequency, Coefficient of  
403 variation of tonic firing frequency, *I<sub>h</sub>* current amplitude, rheobase, action potential threshold, gap between resting  
404 membrane potential and action potential threshold, AP amplitude, action potential duration, after hyperpolarized potential  
405 amplitude, after hyperpolarized potential duration, after hyperpolarized potential peak, latency to fire action potential at  
406 rheobase stimulation, number of action potentials fired at rheobase, number of action potentials fired after  
407 hyperpolarization, maximum number of action potentials fired after depolarization, current to induce maximum number of  
408 action potentials fired, highest firing frequency. Data from each electrophysiological parameter was normalized to  
409 its mean value to prevent over representation of a specific parameter during clustering. Cluster analysis was  
410 performed in R-studio software using K-means method and Euclidean distance. The result of the clustering was  
411 plotted as dendrogram and a hierarchical tree. A principal component analysis was applied to determine the  
412 electrophysiological parameters that best separate the clusters and comparisons between clusters were made  
413 using one-way ANOVA and Tukey's *posthoc* test.

#### 414 Statistical analysis

415 Data in the figures are presented as mean ± SEM, one-way ANOVA or student's t-test were used to compare group of  
416 neurons using prism 5.0 software. *P*< 0.05 was required for significance.

417  
418 **Acknowledgments.** This work was supported by the Intramural Research Program of the National Institute on Drug  
419 Abuse. We thank Drs. David Root and Francois Vautier for setting the colony of *Cre/Flp* transgenic mice at NIDA/IRP.  
420 We also thank Dr. Nirnath Sah (JHU) for advice on cluster analysis.

421 **Author Contributions.** MM and JM-B. conceptualized and initiated the project. JM-B and IC performed  
422 electrophysiological studies. JM-B, IC, GEM-S and EM analyzed electrophysiological data. SM, HW, BL performed  
423 immunolabeling studies and quantified neurons from RNAscope studies. H-LW and BL performed RNAscope studies. SZ  
424 performed confocal studies and data analysis. MM and JM-B and EM prepared the manuscript with contribution from all  
425 authors.

426 **Declaration of Interests.** The authors declare no competing interests.

427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457

458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506


## References

- Barbano, M.F., Wang, H-L., Zhang, S., Miranda-Barrientos, J., Estrin, D.J., Figueroa-Gonzalez, A., Liu, B., Barker, D.J., Morales, M. (2020) VTA glutamatergic neurons mediate innate defensive behaviors. *Neuron*
- Berridge, K.C. (2007) The debate over dopamine's role in reward: the case for incentive salience. *Psychopharmacology (Berl)*. 191(3):391–431.
- Bromberg-Martin, E.S., Matsumoto, M., Hikosaka, O. (2010) Dopamine in motivational control: rewarding, aversive, and alerting. *Neuron*. 68(5):815-34. doi: 10.1016/j.neuron.2010.11.022. Review.
- Bull, F.A., Baptista-Hon, D.T., Lambert, J.J., Walwyn, W., Hales, T.J. (2017) Morphine activation of mu opioid receptors causes disinhibition of neurons in the ventral tegmental area mediated by  $\beta$ -arrestin2 and c-Src. *Sci Rep*. 2017; 7: 9969. Published online 2017 Aug 30. doi: 10.1038/s41598-017-10360-8
- Carr, D.B., Sesack, S.R. (2010) GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex *Synapse*. 38(2):114-23.
- Chen, M., Zhao, Y., Yang, H., Luan, W., Song, J., Cui, D., Dong, Y., Lai, B., Ma, L., Zheng, P. (2015) Morphine disinhibits glutamatergic input to VTA dopamine neurons and promotes dopamine neuron excitation. *Elife*. 4. doi: 10.7554/eLife.09275.
- Chieng, B., Azriel, Y., Mohammadi, S., Christie, M.J. (2011) Distinct cellular properties of identified dopaminergic and GABAergic neurons in the mouse ventral tegmental area. *J Physiol*. 589(Pt 15):3775-87. doi: 10.1113/jphysiol.2011.210807. Epub 2011 Jun 6.
- Fenno, L.E., Mattis, J., Ramakrishnan, C., Hyun, M., Lee, S.Y., He, M., Tucciarone, J., Selimbeyoglu, A., Berndt, A., Grosenick, L., et al. (2014). Targeting cells with single vectors using multiple-feature Boolean logic. *Nat Methods* 11, 763-772.
- Hnasko, T. S., Hjelmstad, G. O., Fields, H. L. & Edwards, R. H. (2012) Ventral tegmental area glutamate neurons: electrophysiological properties and projections. *J. Neurosci*. 32, 15076–15085.
- Johnson, S.W., North, R.A. (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. *J Neurosci* 12: 483–488.
- Jones, S., Kauer, J.A. (1999) Amphetamine depresses excitatory synaptic transmission via serotonin receptors in the ventral tegmental area. *J Neurosci* 19:9780–9787.
- Khaliq, Z.M., Bean, B.P. (2010) Pacemaking in Dopaminergic Ventral Tegmental Area Neurons: Depolarizing Drive from Background and Voltage-Dependent Sodium Conductances *J Neurosci*. 30(21): 7401–7413. doi: 10.1523/JNEUROSCI.0143-10.2010.
- Kudo, T., Uchigashima, M., Miyazaki, T., Konno, K., Yamasaki, M., Yanagawa, Y., Minami, M., Watanabe, M. (2012) Three types of neurochemical projection from the bed nucleus of the stria terminalis to the ventral tegmental area in adult mice. *J. Neurosci*. 32(50):18035-46. doi: 10.1523/JNEUROSCI.4057-12.2012.
- Kudo T, Konno K, Uchigashima M, Yanagawa Y, Sora I, Minami M, Watanabe M. (2014) GABAergic neurons in the ventral tegmental area receive dual GABA/enkephalin-mediated inhibitory inputs from the bed nucleus of the stria terminalis. *Eur J Neurosci*. 39(11):1796-809. doi: 10.1111/ejn.12503.



- 507 Li, X., Qi, J., Yamaguchi, T., Wang, H.L., Morales, M. (2013) Heterogeneous composition of dopamine neurons of  
508 the rat A10 region: molecular evidence for diverse signaling properties. *Brain Struct Funct.* 218(5):1159-76. doi:  
509 10.1007/s00429-012-0452-z. Epub 2012 Aug 29.
- 510
- 511 Margolis, E.B., Hjelmstad, G.O., Bonci, A., Fields, H.L. (2005). Both kappa and mu opioid agonists inhibit  
512 glutamatergic input to ventral tegmental area neurons. *Journal of Neurophysiology* 93:3086–3093. doi:  
513 10.1152/jn.00855.2004.
- 514 Margolis, E. B., Lock, H., Hjelmstad, G. O. & Fields, H. L. (2006) The ventral tegmental area revisited: is  
515 there an electrophysiological marker for dopaminergic neurons? *J. Physiol.* 577, 907–924.
- 516 Margolis, E. B., Toy, B., Himmels, P., Morales, M. & Fields, H. L. (2012) Identification of rat ventral  
517 tegmental area GABAergic neurons. *PLoS ONE* 7, e42365.
- 518 Monteggia, L.M., Eisch, A.J., Tang, M.D., Kaczmarek, L.K., Nestler, E.J. (2000) Cloning and localization of the  
519 hyperpolarization-activated cyclic nucleotide-gated channel family in rat brain. *Brain Res Mol Brain Res.* 81(1-  
520 2):129-39.
- 521
- 522 Morales, M., Margolis, E.B. (2017) Ventral tegmental area: cellular heterogeneity, connectivity and behaviour. *Nat*  
523 *Rev Neurosci.* 18(2):73-85. doi: 10.1038/nrn.2016.165. Epub 2017 Jan 5. Review
- 524
- 525 Nieh, E.H., Matthews, G.A., Allsop, S.A., Presbrey, K.N., Leppla, C.A., Wichmann, R., Neve, R., Wildes, C.P., Tye,  
526 K.M. (2015) Decoding neural circuits that control compulsive sucrose seeking. *Cell.* 160(3):528-41. doi:  
527 10.1016/j.cell.2015.01.003.
- 528
- 529 Notomi, T., Shigemoto, R. (2004) Immunohistochemical localization of Ih channel subunits, HCN1-4, in the rat brain.  
530 *J Comp Neurol.* 471(3):241-76.
- 531
- 532 Ntamati, Niels R., Creed, Meaghan, Achargui Ridouane, Lüscher Christian (2018) Periaqueductal efferents to  
533 dopamine and GABA neurons of the VTA *PLoS One.* 13(1): e0190297. Published online 2018 Jan  
534 5. doi: 10.1371/journal.pone.0190297
- 535
- 536 Omelchenko, N., Bell, R., Sesack, SR. (2009) Lateral habenula projections to dopamine and GABA neurons in the rat  
537 ventral tegmental area. *Eur J Neurosci.* 30(7):1239-50. doi: 10.1111/j.1460-9568.2009.06924.x. Epub 2009 Sep 29
- 538
- 539 Omelchenko, N., Sesack, SR. (2010) Periaqueductal gray afferents synapse onto dopamine and GABA neurons in the  
540 rat ventral tegmental area *J Neurosci Res.* 88(5):981-91. doi: 10.1002/jnr.22265..  
541 PMID:
- 542
- 543 Root, D.H., Estrin, D.J., Morales, M. (2018b) Aversion or Salience Signaling by Ventral Tegmental Area Glutamate  
544 Neurons. *iScience.* 2:51-62. doi: 10.1016/j.isci.2018.03.008.
- 545
- 546 Root, D.H., Mejias-Aponte, C.A., Zhang, S., Wang, H.L., Hoffman, A.F., Lupica, C.R., and Morales, M.  
547 (2014). Single rodent mesohabenular axons release glutamate and GABA. *Nat Neurosci* 17, 1543-1551.
- 548
- 549 Root, D.H., Zhang, S., Barker, D.J., Miranda-Barrientos, J., Liu, B., Wang, H.L., and Morales, M. (2018).  
550 Selective Brain Distribution and Distinctive Synaptic Architecture of Dual Glutamatergic-GABAergic  
551 Neurons. *Cell Rep* 23, 3465-3479
- 552
- 553 Tan, K.R., Yvon, C., Turiault, M., Mirzabekov, J.J., Doehner, J., Labouèbe, G., Deisseroth, K., Tye, K.M.,  
554 Lüscher (2012) GABA neurons of the VTA drive conditioned place aversion. *Neuron* 73, 1173–1183.
- 555 Tateno, T. Robinson, H.P. (2011) The mechanism of ethanol action on midbrain dopaminergic neuron firing: a  
556 dynamic-clamp study of the role of I(h) and GABAergic synaptic integration. *J Neurophysiol.* 106(4):1901-22. doi:  
557 10.1152/jn.00162.2011. Epub 2011 Jun 22

- 558 Tracy, M.E., Tesic, V., Stamenic, T.T., Joksimovic, S.M., Busquet, N., Jevtovic-Todorovic, V., Todorovic, S.M.  
559 (2018) Cav3.1 isoform of T-type calcium channels supports excitability of rat and mouse ventral tegmental area  
560 neurons. *Neuropharmacology*. 135:343-354. doi: 10.1016/j.neuropharm.2018.03.028. Epub 2018 Mar 23.  
561
- 562 van Zessen, R., Phillips, J. L., Budygin, E. A. & Stuber, G. D. (2012) Activation of VTA GABA neurons  
563 disrupts reward consumption. *Neuron* 73, 1184–1194.  
564 Wise RA (2004) Dopamine, learning and motivation. *Nat Rev Neurosci*. 2004;5:483–494.  
565
- 566 Woodward, T.J., Tesic, V., Stamenic, T.T., Jevtovic-Todorovic, V., Todorovic, S.M. (2019) Pharmacological  
567 Antagonism of T-Type Calcium Channels Constrains Rebound Burst Firing in Two Distinct Subpopulations of  
568 GABA Neurons in the Rat Ventral Tegmental Area: Implications for  $\alpha$ -Lipoic Acid. *Front Pharmacol*. 10:1402. doi:  
569 10.3389/fphar.2019.01402. eCollection 2019.  
570
- 571 Yamaguchi, T., Sheen, W., Morales, M. (2007) Glutamatergic neurons are present in the rat ventral  
572 tegmental area. *Eur J Neurosci* 25:106–118.  
573
- 574 Zhang, W., Yang, H.L., Song, J.J., Chen, M., Dong, Y., Lai, B., Yu, Y.G., Ma, L., Zheng, P. (2015)  
575 DAMGO depresses inhibitory synaptic transmission via different downstream pathways of  $\mu$   
576 opioid receptors in ventral tegmental area and periaqueductal gray. *Neuroscience*. 301:144-54. doi:  
577 10.1016/j.neuroscience.2015.05.077. Epub 2015 Jun 3.  
578
- 579 Zhou, Z., Liu, X., Chen, S., Zhang, Z., Liu, Y., Montardy, Q., Tang, Y., Wei, P., Liu, N., Li, L., Song, R., Lai, J., He,  
580 X., Chen, C., Bi, G., Feng, G., Xu, F., Wang, L. (2019) A VTA GABAergic Neural Circuit Mediates Visually Evoked  
581 Innate Defensive Responses. *Neuron*. 103(3):473-488.e6. doi: 10.1016/j.neuron.2019.05.027. Epub 2019 Jun 12.  
582



583

584

585

586

587


588

589


590

591

**Figure 1. Selective targeting of VTA VGlut2<sup>+</sup> VGaT<sup>+</sup>, VGlut2<sup>+</sup> VGaT<sup>-</sup> and VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons. (A-C)** Crossing of *vglut2-Cre* and *vgat-Flp* mice to generate *vglut2-Cre/vgat-Flp* mouse and intra-VTA injections of INTRASECT AAV-C<sub>ON</sub>/F<sub>ON</sub>-eYFP to target VGlut2<sup>+</sup> VGaT<sup>+</sup> neurons, AAV-C<sub>ON</sub>/F<sub>OFF</sub>-eYFP to target VGlut2<sup>+</sup> VGaT<sup>-</sup> neurons or AAV-C<sub>OFF</sub>/F<sub>ON</sub>-eYFP vectors to target VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons. **(D)** Co-expression of VGlut2 mRNA and VGaT mRNA in VTA VGlut2<sup>+</sup> VGaT<sup>+</sup> eYFP neuron. **(E)** VGlut2 mRNA without VGaT mRNA in VTA VGlut2<sup>+</sup> VGaT<sup>-</sup> eYFP neuron. **(F)** VGaT mRNA without VGlut2 mRNA in VTA VGlut2<sup>-</sup> VGaT<sup>+</sup> eYFP neuron. Scale bar =20  $\mu$ m **(G)** Total percentage of VTA transfected neurons co-expressing VGlut2 mRNA or VGaT mRNA (n= 3 mice per group).




**Figure 2. Spontaneous firing activity in VTA VGlut2<sup>+</sup> VGaT<sup>+</sup>, VGlut2<sup>+</sup> VGaT<sup>-</sup>, and VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons during *ex vivo* cell attached recordings.** (A) Schematic representation of intra-VTA injections of vectors (AAV-C<sub>ON</sub>/F<sub>ON</sub>- eYFP, AAV-C<sub>ON</sub>/F<sub>OFF</sub>-eYFP and AAV-C<sub>OFF</sub>/F<sub>ON</sub>- eYFP) in *vglut2-Cre/vgat-Flp* mice. (B) Traces recorded in the cell attached configuration in horizontal slices from identified spontaneously active VTA neurons. (C) Proportion of VTA spontaneously active vs quiescent neurons. (D) Summary of spontaneous firing rate across VTA neurons. VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons have higher firing frequencies than VGlut2<sup>+</sup> VGaT<sup>+</sup> and VGlut2<sup>+</sup> VGaT<sup>-</sup> neurons. One-way ANOVA  $F_{2,77} = 5.795$   $p = 0.046$ ; Tukey's *post hoc* test  $*p < 0.05$ . (E) There is no relationship between firing frequency and coefficient of variation (CV) of inter-spike intervals (ISIs) for these neuronal types. **Inset**, summary of CV of ISIs in VGlut2<sup>+</sup> VGaT<sup>+</sup>, VGlut2<sup>+</sup> VGaT<sup>-</sup>, and VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons. Example traces (F) and summary durations (G) of extracellular recorded APs. One-way ANOVA  $F_{2,77} = 6.745$   $p = 0.0026$ ; Tukey's *post hoc* test  $*p < 0.05$ ,  $**p < 0.01$




605  
606  
607  
608  
609  
610  
611

**Figure 3. Many VTA VGlut2<sup>+</sup> VGaT<sup>+</sup>, VGlut2<sup>+</sup> VGaT<sup>-</sup>, and VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons have an I<sub>h</sub>.** (A) Voltage clamp (top; step from -60 mV to -120 mV, 1s duration) and current clamp (bottom; step from 0 pA to 50-100 pA to reach mV= -120 mV) traces of I<sub>h</sub> measurements in VTA neurons. I<sub>h</sub> was blocked by ZD 7288 (5 μM; gray traces). (B) Proportion of each VTA neuronal types that expressed I<sub>h</sub>. (C) Smaller I<sub>h</sub> amplitude was observed in VGlut2<sup>+</sup> VGaT<sup>+</sup> neurons compared to VGlut2<sup>+</sup> VGaT<sup>-</sup> or VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons. One-way ANOVA F<sub>2,82</sub> = 3.528 p = 0.034, Tukey's *post hoc* test \*p < 0.05.







**Figure 4. Stimulated firing patterns of VTA VGLuT2<sup>+</sup> VGaT<sup>+</sup>, VGLuT2<sup>+</sup> VGaT<sup>-</sup>, and VGLuT2<sup>-</sup> VGaT<sup>+</sup> neurons.** (A) Example current clamp traces of VTA neurons with long or short latency AP firing in response to injected current steps. (B) VGLuT2<sup>+</sup> VGaT<sup>+</sup>, VGLuT2<sup>+</sup> VGaT<sup>-</sup>, and VGLuT2<sup>-</sup> VGaT<sup>+</sup> neurons with short or long latency to first AP. One-way ANOVA  $F_{4,139} = 107.8$   $p < 0.0001$ , Tukey's *post hoc* test  $***p < 0.0001$  (C) Evoked AP firing in VGLuT2<sup>+</sup> VGaT<sup>+</sup>, VGLuT2<sup>+</sup> VGaT<sup>-</sup>, and VGLuT2<sup>-</sup> VGaT<sup>+</sup> neurons. Neurons with long latency to firing mostly required current injections  $>40$  pA to drive firing. One-way ANOVA  $F_{4,13} = 32.49$   $p < 0.0001$ , Tukey's *post hoc* test  $***p < 0.0001$ . (D) Example firing patterns in response to injected current steps sorted by long or short latency to firing. Short latency firing VGLuT2<sup>+</sup> VGaT<sup>+</sup> and VGLuT2<sup>+</sup> VGaT<sup>-</sup> neurons go into depolarization block, show continuous firing with adaptation, or show continuous firing without adaptation. VGLuT2<sup>-</sup> VGaT<sup>+</sup> neurons only show responses of continuous firing with or without adaptation.



623  
 624 **Figure 4-figure supplement 1. Neurons that fire with adaptation during depolarizing current steps have**  
 625 **larger inter-spike intervals (ISIs) than neurons without adaptation. (A-C)** Normalized ISI of the first 10  
 626 AP fired after 150 pA current injection from **(A)** VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons with adaptation and without  
 627 adaptation. Two way ANOVA spike number x type of neuron  $F_{9,250} = 4.72$   $p < 0.0001$ , type of neuron  $F_{1,250} =$   
 628  $121.44$   $p < 0.0001$ , spike number  $F_{9,250} = 5.73$   $p < 0.0001$  Bonferroni posthoc test \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . **(B)**  
 629 VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons with adaptation and without adaptation Two way ANOVA spike number x type of  
 630 neuron  $F_{9,220} = 5.08$   $p < 0.0001$ , type of neuron  $F_{1,220} = 147.51$   $p < 0.0001$ , spike number  $F_{9,220} = 11.31$   $p < 0.001$ .  
 631 Bonferroni posthoc test \* $p = 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  and **(C)** VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons with adaptation  
 632 and without adaptation Two way ANOVA spike number x type of neuron  $F_{9,360} = 1.39$   $p = 0.1904$ , type of  
 633 neuron  $F_{1,360} = 38.80$   $p < 0.0001$ , spike number  $F_{9,360} = 2.48$   $p < 0.094$ . Bonferroni posthoc test \* $p = 0.05$ , \*\* $p <$   
 634  $0.01$ .  
 635




**Figure 4-figure supplement 2.  $I_A$  mediates long latency AP firing.** (A) Example current clamp (top) and voltage clamp (bottom) traces in a VGlut2<sup>+</sup> VGaT<sup>-</sup> long latency neuron (B) Example voltage clamp traces from a VGlut2<sup>+</sup> VGaT<sup>-</sup> long latency neuron at baseline and after bath application of the  $I_A$  blocker 4-Aminopyridine (4-AP) (top). Mean  $I_A$  amplitude responses across different voltage steps at baseline (close circles) and after bath application of 4-AP (open triangles) (bottom) (n= 12 neurons, 3 VGlut2<sup>+</sup> VGaT<sup>+</sup> neurons and 9 VGlut2<sup>+</sup> VGaT<sup>-</sup>) (C) Example current clamp traces (left) of a long latency VGlut2<sup>+</sup> VGaT<sup>+</sup> neuron during depolarizing step current injections before and after bath application of 4-AP. Input/output curves show 4-AP (open triangles) increased number of APs fired during depolarizing current injections compared to baseline (closed circles) (n= 8 neurons, 4 VGlut2<sup>+</sup> VGaT<sup>+</sup> neurons and 4 VGlut2<sup>+</sup> VGaT<sup>-</sup> neurons) Two way ANOVA 4-AP x current  $F_{15,112} = 0.83$   $p = 0.6408$ , 4-AP  $F_{15,112} = 49.06$   $p < 0.0001$ , current  $F_{15,112} = 4.64$   $p < 0.0001$ . (D-E) Example firing pattern during injected current steps in a VGlut2<sup>+</sup> VGaT<sup>+</sup> long latency neuron at baseline (D) and after bath application of 4-AP (E). (F) 4-AP decreased the latency to AP firing during the minimum injected current step in long latency neurons (n= 8 neurons, 4 VGlut2<sup>+</sup> VGaT<sup>+</sup> and 4 VGlut2<sup>+</sup> VGaT<sup>-</sup>). Paired *t*-test  $t_7 = 8.877$   $***p < 0.0001$  (G) 4-AP increased total number of APs fired after activation across long latency neurons during an input/output curve (10 – 150 pA, 500 ms). Paired *t*-test  $t_7 = 2.426$   $*p = 0.0457$  (n= 8 neurons 4 VGlut2<sup>+</sup> VGaT<sup>+</sup> and 4 VGlut2<sup>+</sup> VGaT<sup>-</sup>)



654  
655

**Figure 5. Rebound firing neurons is mediated by  $I_h$  and T-type calcium channels in VGluT2<sup>+</sup> VGaT<sup>+</sup>, VGluT2<sup>+</sup> VGaT<sup>-</sup>, and VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons.** (A) Example current clamp traces (top) and proportion of neurons showing rebound firing (bottom) among VGluT2<sup>+</sup> VGaT<sup>+</sup> (purple), VGluT2<sup>+</sup> VGaT<sup>-</sup> (green), and VGluT2<sup>-</sup> VGaT<sup>+</sup> (red) neurons. (B) Number of rebound APs fired by VGluT2<sup>+</sup> VGaT<sup>+</sup> (purple), VGluT2<sup>+</sup> VGaT<sup>-</sup> (green), and VGluT2<sup>-</sup> VGaT<sup>+</sup> (red) neurons. (C) Example recordings in which rebound firing was blocked by ZD 7288 (5μM) (black traces). (D). Example recordings in which rebound firing was blocked by Mibefradil (1μM) (black traces).



663

664

665

666


667

668


669

**Figure 5-figure supplement 1. Rebound firing is stable across time.** (A) Current clamp traces from a VGluT2<sup>-</sup> VGaT<sup>+</sup> neuron with rebound firing at the beginning of the experiment (0 minutes) and after 10 minutes. (B) Number of rebound APs in at the beginning of the experiment (0 minutes) and after 10 minutes of recording (n= 8 neurons, 2 VGluT2<sup>+</sup> VGaT<sup>+</sup> neurons, 2 VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons, and 4 VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons)






670  
 671 **Figure 6. Hierarchical cluster analysis of electrophysiological properties of VTA VGluT2<sup>+</sup> VGaT<sup>+</sup>,**  
 672 **VGluT2<sup>+</sup> VGaT<sup>-</sup>, and VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons.** (A) Dendrogram and heat map of VTA neuronal  
 673 electrophysiological properties. (B) Neurotransmitter neuronal phenotype distributions across clusters. (C)  
 674 Example current clamp traces from neurons within each cluster in response to hyperpolarizing and depolarizing  
 675 current injections. (D) Examples of firing patterns over time during depolarization steps in neurons within each  
 676 cluster. (E) Membrane potentials of neurons in each cluster. One-way ANOVA  $F_{3,130} = 28.25$   $p < 0.0001$ , Tukey's  
 677 *post hoc* test  $**p < 0.001$   $***p < 0.0001$ . (F) Rheobase of neurons in each cluster. One-way ANOVA  $F_{3,130} =$   
 678  $42.45$   $p < 0.0001$ , Tukey's *post hoc* test  $***p < 0.0001$ . (G) Latency to fire APs in response to depolarizing  
 679 current steps in neurons in each cluster. One-way ANOVA  $F_{3,130} = 134.9$   $p < 0.0001$ , Tukey's *post hoc* test  $*p <$   
 680  $0.05$   $***p < 0.0001$ . (H) Maximum number of APs fired during depolarizing current steps (500 ms) of neurons  
 681 in each cluster. One-way ANOVA  $F_{3,130} = 30.64$   $p < 0.0001$ , Tukey's *post hoc* test  $*p < 0.0001$ .




682  
683  
684  
685  
686  
687

**Figure 7. Topographic locations of VTA neurons by physiological cluster.** (A) Schematic representations of dorsal, middle, and ventral horizontal VTA slices. (B-E) locations of recorded neurons from cluster 1 (B), cluster 2 (C), cluster 3 (D), and cluster 4 (E) in dorsal, middle, and ventral horizontal VTA slices. Grey dotted line divides the medial and lateral VTA. Each circle represents a single recorded neuron.



**Figure 8. Functional MORs are present in VGlut2<sup>+</sup> VGaT<sup>-</sup> and VGlut2<sup>-</sup> VGaT<sup>+</sup> VTA neurons.** Detection of mRNA encoding VGlut2 (red), VGaT (green) or Oprm1 (white) and TH protein (cyan). (A) example neuron co-expressing VGlut2 and Oprm1 mRNAs. (B) example neuron co-expressing VGaT and Oprm1 mRNAs. (C) example neuron co-expressing VGlut2, VGaT, and Oprm1 mRNAs. (D) Percentage of VTA neurons expressing VGlut2 or VGaT mRNA with Oprm1 mRNA (3 mice). (E) Example current clamp traces from a VGlut2<sup>+</sup> VGaT<sup>-</sup> (left) and a VGlut2<sup>-</sup> VGaT<sup>+</sup> (right) neuron responsive to DAMGO bath application (F) Time course average showing-membrane potential of VGlut2<sup>+</sup> VGaT<sup>-</sup> and VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons in response to DAMGO. (G) Summary of DAMGO-induced changes in membrane potential in VGlut2<sup>+</sup> VGaT<sup>-</sup> and VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons. Responses in green and red circles and nonrespondes in grey circles. Paired *t*-test before and after DAMGO application  $t_6 = 4.042$   $p = 0.0068$  for VGlut2<sup>+</sup> VGaT<sup>-</sup> neurons,  $t_{10} = 5.991$   $p = 0.0002$  for VGlut2<sup>-</sup> VGaT<sup>+</sup> neurons. (H) Example current clamp traces showing depolarizations in response to the  $\mu$ -opioid receptor selective antagonist CTAP in neurons that were hyperpolarized by DAMGO. (I) Time course of average membrane potential in neurons with application of DAMGO and CTAP. Repeated measures ANOVA  $F_{2,14} = 15.0$   $p < 0.0003$ , Dunnett's multiple comparison test  $p < 0.0001$  for VGlut2<sup>+</sup> VGaT<sup>-</sup>;  $F_{2,17} = 3.638$   $p < 0.0011$ , Dunnett's multiple comparison test  $p < 0.0001$  for VGlut2<sup>-</sup> VGaT<sup>+</sup>.



706  
707 **Figure 8-figure supplement 1. VGluT2<sup>+</sup> VGaT<sup>-</sup> and VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons are inhibited by DAMGO**  
708 **in the presence of GABA<sub>A</sub> receptor antagonist Bicuculline.** (A) Example current clamp of a VGluT2<sup>+</sup> VGaT<sup>-</sup>  
709 neuron that responded to DAMGO in the presence of GABA<sub>A</sub> receptor antagonist Bicuculline. (B) Mean time  
710 course showing the change in membrane potential across VGluT2<sup>+</sup> VGaT<sup>-</sup> neurons (n= 4) to application of  
711 DAMGO in the presence of Bicuculline. (C) Example current clamp trace of a VGluT2<sup>-</sup> VGaT<sup>+</sup> neuron that  
712 responded to DAMGO in the presence of the GABA<sub>A</sub> receptor antagonist Bicuculline. (D) Mean time course of  
713 the membrane potential of VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons in response to DAMGO in the presence of Bicuculline (n=  
714 5).

Class of VTA neuron	*Membrane potential (mV)	Membrane resistance (MOhms)	Capacitance (pF)	*Rheobase (pA)	AP Threshold (mV)	Gap (mV)	AP amplitude (mV)	*AP duration (ms)
VGluT2 <sup>+</sup> VGaT <sup>+</sup> (N=52)	-68.0 ± 1.2	644.7 ± 68.4	30.9 ± 2.0	29.0 ± 5.5	-39.1 ± 0.5	28.8 ± 1.3	70.7 ± 1.3	2.2 ± 0.1
VGluT2 <sup>+</sup> VGaT <sup>-</sup> (N=48)	-64.6 ± 0.9	655.7 ± 42.5	26.6 ± 1.3	37.3 ± 5.6	-36.7 ± 0.7	28.0 ± 1.0	69.7 ± 1.0	2.9 ± 0.2
VGluT2 <sup>-</sup> VGaT <sup>+</sup> (N=41)	-59.6 ± 0.9	549.7 ± 53.7	30.6 ± 1.6	14.9 ± 2.9	-38.4 ± 0.8	21.1 ± 0.9	72.9 ± 1.6	1.8 ± 0.1

**Table 1. Intrinsic membrane and action potential properties in VTA VGluT2<sup>+</sup> VGaT<sup>+</sup>, VGluT2<sup>+</sup> VGaT<sup>-</sup>, and VGluT2<sup>-</sup> VGaT<sup>+</sup> neurons.** Action potential (AP). Difference from membrane potential and action potential threshold (Gap). Millivolts (mV). Megaohms (MOhms). Picofarads (pF). Picoamperes (pA). Milliseconds (ms). Membrane potential: One-way ANOVA  $F_{2,140} = 16.65$   $p < 0.0001$ ; Tukey's *post hoc* test \*VGluT2<sup>+</sup> VGaT<sup>+</sup> vs VGluT2<sup>+</sup> VGaT<sup>-</sup>  $p < 0.05$ , \*\*VGluT2<sup>+</sup> VGaT<sup>-</sup> vs VGluT2<sup>-</sup> VGaT<sup>+</sup>  $p < 0.01$ , \*\*\*VGluT2<sup>+</sup> VGaT<sup>+</sup> vs VGluT2<sup>-</sup> VGaT<sup>+</sup>  $p < 0.001$ . Rheobase: One-way ANOVA  $F_{2,140} = 4.571$   $p = 0.0120$ ; Tukey's *post hoc* test \*\*VGluT2<sup>+</sup> VGaT<sup>-</sup> vs VGluT2<sup>-</sup> VGaT<sup>+</sup>  $p < 0.01$ . Gap: One-way ANOVA  $F_{2,130} = 12.37$   $p < 0.0001$ ; Tukey's *post hoc* test \*\*\*VGluT2<sup>+</sup> VGaT<sup>+</sup> vs VGluT2<sup>-</sup> VGaT<sup>+</sup>  $p < 0.001$ , \*\*\*VGluT2<sup>+</sup> VGaT<sup>-</sup> vs VGluT2<sup>-</sup> VGaT<sup>+</sup>  $p < 0.001$ . AP duration: One-way ANOVA  $F_{2,140} = 17.26$   $p < 0.0001$ ; Tukey's *post hoc* test \*\*VGluT2<sup>+</sup> VGaT<sup>+</sup> vs VGluT2<sup>+</sup> VGaT<sup>-</sup>  $p < 0.001$ , \*\*\*VGluT2<sup>+</sup> VGaT<sup>-</sup> vs VGluT2<sup>-</sup> VGaT<sup>+</sup>  $p < 0.001$ .